Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease

Is this Study for You?

Let's Get Started!

Description

Participation involves taking the study drug empagliflozin or a placebo for 12 months. Blood sample collection, magnetic resonance imaging (MRI) of the kidneys and blood vessel stiffness testing during visits at baseline, 3-month and 12-month to the Renal Research Clinic located at the University of Colorado Anschutz Medical Campus or the University and regular telephone or telemedicine visits. If traveling to the University of Colorado from out-of-state, your airfare and hotel will be arranged and paid for by the study.

Details
Age

Adult

Eligibility

-Age 18-50 years -Diagnosis of autosomal dominant polycystic kidney disease (ADPKD) -GFR 30 - 90 mL/min/1.73 m2 -Rapidly progressing disease based on Mayo imaging class 1C, 1D or 1E -No diabetes or heart failure -Not taking JYNARQUE (tolvaptan) or diuretic medication

Type of Study

Treatment

Scope

National

Locations

Brain Imaging Center (BIC)
Renal Research Center
University of Colorado Hospital

Principal Investigator
Photograph of Michel Chonchol,  MD

Michel Chonchol, MD

Study ID

Protocol Number: 22-0616

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers